OstriGen is working with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the efficacy of our ostrich antibodies in countering a number of viral threats.
Antibodies for the Zaire strain (EBOV) and Sudan strain (SUDV) of Ebola viruses as well as the MERS-CoV virus have been tested with positive in vitro results in neutralizing these dangerous viruses. USAMRIID has also done mouse testing with the SUDV antibodies, and they will now test our Zika antibodies.
Childhood Enteric Disease Ostrich Egg Regimen (CEDOER)
The Mozambique government has approved a study of the use of ostrich antibodies in preventing childhood enteric diarrheal disease in a rural village in northern Mozambique.
Antibodies to Norovirus, E. coli, Salmonella, and Shigella, as well as antibodies to cholera toxin have been created. This cocktail of antibodies will be embedded within the crystal structure of a hard candy. It has already been established that the properties of the antibodies are preserved by this means.
Anticipating a 2017 start, we will collaborate with the medical faculty and students of nearby Lurio University.
In collaboration with the Clostridium difficile Laboratory at the Beth Israel Deaconess Medical Center/Harvard University, we are developing ostrich antibodies to the two toxins produced during Clostridium difficile infection.
The antibodies will be tested in vitro and then will be used in a mouse study.
Massachusetts General Hospital/Harvard University has provided us with two experimental cholera vaccines that we will use to produce ostrich antibodies against cholera.
We will then provide the produced antibodies to Massachusetts General Hospital for use in animal testing.